Zheng Bian

Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve.

Fullgoal Fund Management Co., Ltd. (Fullgoal Fund) is an independent Chinese fund management firm which was founded in 1999. In 2003, the firm was restructured when the Bank of Montreal took a strategic interest in them and brought international concepts and management techniques to Fullgoal Fund. Headquartered in Shanghai, Fullgoal Fund provides investment management solutions including open and closed-end mutual funds, qualified domestic institutional investor (QDII) funds, enterprise annuity funds, domestic social security funds and asset management to segregated accounts for both domestic and international clients.

Guotai Junan Securities Co. Ltd. (Broker) (GTJA-Broker) is the securities brokerage division of Guotai Junan Securities Co. Ltd. (SHA: 601211), which is headquartered in Shanghai, China. GTJA-Broker provides securities brokerage services to institutional investors.

Founded in 1990, Part of Sunwah Kingsway Capital Holdings Ltd., Kingsway Financial Services Group Ltd. is a financial services company based in Hong Kong, Hong Kong. The Chinese company's description simply states "it works!"

Bosera Asset Management Co., Ltd. (Bosera AM) is an independent Chinese asset management firm which was founded in 1998. Formerly known as Boshi Fund Management, the firm is headquartered in Shenzhen with branches in Beijing, Shanghai, Zhengzhou, Shenyang and Chengdu. Bosera AM provides professional investment services for clients, with business covering fund raising, fund distribution, asset management and any other businesses permitted by China Securities Regulatory Commission. Authorized by the National Council of Social Security Fund, the firm manages part of the National Social Security Fund portfolios. In addition, Bosera AM provides investment management services to several corporate pension funds and segregated accounts.

CPIC Fund Management Co. Ltd. (CPIC Fund Management) is the asset management subsidiary of Pacific Asset Management Co. Ltd., which is owned by China Pacific Insurance (Group) Co., Ltd. (SHA: 601601) in China. The firm was originally founded as Guotai Junan Allianz Fund Management Co., Ltd. through a joint venture between Guotai Junan Securities Co., Ltd. (China) and Allianz AG (Germany) in 2003. CPIC Fund Management is headquartered in Shanghai and provides fund management services to individual and institutional investors.

Guosen Securities Co., Ltd. (Broker) (GSEC-Broker) is the broker/dealer division of Guosen Securities Co., Ltd. (SHE: 002736), a financial services company headquartered in Shenzhen, China. The firm was founded in 1994 as Shenzhen SDIC Securities Co., Ltd. GSEC-Broker provides retail clients with a full range of services such as securities trading, investment consulting, margin financing, stock pledge financing, futures IB, and financial product agency sales.

Harvest Fund Management Co., Ltd. (HFM) is an independent Chinese investment advisory firm which was founded in 1999. In 2005, they became a joint venture between China Credit Trust Co., Ltd. (40%), Lixin Investment Co., Ltd. (30%) and Deutsche Asset Management Co., Ltd. (30%). Headquartered in Beijing with additional office in Shanghai, the firm offers a range of domestic equity and fixed-income funds for individual, retail, institutional and Enterprise Annuity investors based in China. HFM is a responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI).

Hwabao WP Fund Management Co., Ltd. (Hwabao FM) is an independent Chinese fund management firm which was founded as a joint venture between Baosteel Group (HWABAO Trust Co. Ltd.) and Societe Generale Group in 2003. It is now owned by Hwabao Trust Co., Ltd. (51%), Warburg Pincus Asset Management LP (29%) and Jiangsu Railway Group Co., Ltd. (20%). Headquartered in Shanghai, Hwabao FM manages funds for institutional investors.

Everbright PGIM Fund Management Co. Ltd. (Everbright PGIM) is a China-based joint venture firm between Everbright Securities Co. Ltd., a subsidiary of majority shareholder, state-controlled China Everbright Group Corp. and Pramerica Investment Management, a subsidiary of US-based Prudential Financial, Inc. (NYSE: PRU). The firm was founded in 2004 and as Everbright Pramerica Fund Management Co., Ltd. Headquartered in Shanghai, Everbright PGIM manages mutual funds distributed to Chinese retail investors through banks and brokerage firms.

Chang Xin Asset Management Co., Ltd. (Chang Xin AM) is a fund management firm headquartered in Shanghai, China. Founded in 2003, Chang Xin AM manages the ChangXin range of open-end mutual funds.

Ping An Securities Co. Ltd. is the securities brokerage subsidiary of Ping An Trust Co., Ltd., which is owned by Ping An Insurance (Group) Co. of China Ltd. (SHA: 601318; HKG: 2318). Headquartered in Shenzhen, the firm was founded in 1991 and provides institutional brokerage services based on the needs of professional investors such as private equity, public equity, trust, asset management, general corporate institutions, and high-net-worth clients.

UBS Securities Co. Ltd. is the Chinese brokerage subsidiary of UBS Group AG (SWX: UBSG) in Switzerland. Headquartered in Beijing, the firm was founded in 2006 as Beijing Securities Co. Ltd. They provide securities brokerage services to domestic corporate and institutional clients, and qualified foreign institutional investors (QFII).

China Merchants Securities (HK) Co., Ltd. is a Chinese company that provides brokerage services. It is based in Hong Kong, Hong Kong and ultimately controlled by the Government of China. The company was founded in 1986.

Zhonghai Fund Management Co., Ltd. operates as an independent investment adviser. It manages a range of funds and provides investment advice. Its business scope covers fund raising, fund sales, and asset management. The company was founded on March 18, 2004 and is headquartered in Shanghai, China.

AXA-SPDB Investment Managers Co., Ltd. (AXA-SPDB IMCL) is an independent investment management firm which was established in 2007 as a joint venture between Shanghai Pudong Development Bank Co., Ltd. (SPDB), AXA Investment Managers SA and Shanghai Sheng Rong Investment Company. Based in Shanghai, AXA-SPDB IMCL provides a range of services including securities investment fund raising, fund sales and asset management.

SWS Research Co., Ltd. is the investment research subsidiary of Shenwan Hongyuan Securities Co., Ltd., which is owned by Shenwan Hongyuan Group Co., Ltd. (SHE: 000166) in China. Headquartered in Shanghai, the firm was founded in 1992 to offer a wide range of products and services to global investors who want to invest in Chinese equity market. SWS Research provides clients with securities research service that covers over 500 key stocks in Asian market, as well as economics, strategy, bond, fund and derivatives research. Their clients include almost all major domestic institutional investors such as mutual funds, insurance companies, banks and trusts. They also serve QFII and other overseas institutional investors.

Wolfe Research LLC is a FINRA-registered sell-side research firm headquartered in New York City. The firm was founded by Edward Wolfe in 2008 and is a subsidiary of Wolfe Holdco LLC. Wolfe Research provides bespoke research of various stocks in every major GIC sector for institutional clients. The firm has established a reputation for macro research underpinning coverage in Industrials, Utilities/Energy, Consumer/Retail, Financials/REITS, Healthcare and TMT.

ICBC Asset Management (Global) Co., Ltd. (ICBCAMG) is an investment management firm headquartered in Hong Kong. Formerly known as Worldsec Asset Management Ltd., the firm was founded in 1991 and became a wholly owned subsidiary of Industrial & Commercial Bank of China (Asia) Ltd. in 2008. They are ultimately owned by Industrial & Commercial Bank of China Ltd. (SHA: 601398, HK:1398) in China. ICBCAMG is positioned as the global asset management platform of Industrial and Commercial Bank of China Group (ICBC Group). They provivde investment products and services to institutional and retail clients.

Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.

Haitong Securities Asset Management Co., Ltd. (Haitong Asset Management) is the wholly-owned subsidiary of Haitong Securities Co., Ltd. (SH: 600837; HK: 6837; OTC: HAITY) in China. Established in 2012, the firm is based in Shanghai and provides asset management brokerage services for institutional and individual investors.

RHB Securities Hong Kong Ltd. (RHBHK) is a brokerage firm headquartered in Hong Kong. The firm was founded in 2013 and is owned by RHB Hong Kong Ltd., ultimately held by RHB Bank Bhd. (KLSE: RHBBANK) in Malaysia. RHBHK provides stock broking and derivatives trading services catering both retail clients and institutional investors.

China Universal Asset Management (Hong Kong) Co. Ltd. (China Universal HK) is the wholly owned, Hong Kong-based asset management subsidiary of China Universal Asset Management Co. Ltd., an investment management company headquartered in Shanghai, China. Founded in 2009, China Universal HK manages investment funds, provides investment advisory services, and manages discretionary accounts for domestic Chinese institutional and individual investors.

Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sales service of three types of implanted medical devices. Its products include neurosurgery products, cardiothoracic surgery products, neurospine products, and oral implant system. Its products are used in neurosurgery, skull repair, and cardiothoracic surgery. The company was founded by Li Ren Hu, Li Gong Hu and Di Yuan Huang on March 14, 2005 and is headquartered in Xi'an, China.

Ningbo Taikang Pharmaceutical Technology Co. Ltd. is a private company that develops pharmaceutical technology. The company is based in Ningbo, China.

Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.

Shanghai Ennovabio Pharmaceuticals Co. Ltd. is a private company that manufactures pharmaceutical products. The company is based in Shanghai, China.

Suzhou Kintor Pharmaceuticals, Inc. engages in the technology research and development, technical services, transfer, and advice of drugs and reagents. The company was founded by Youzhi Tong on March 24, 2009 and is headquartered in Suzhou, China.

Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.

SATP Holding, Inc. operates as a holding company, which provides finance and taxation solutions to small and medium businesses. It operates through following segments: SaaS-based solutions, SaaS-based Solutions-Regional partners and Professional services. The SaaS-based Solutions segment engages in developing and offering innovative solutions, primarily through its proprietary SATP system. The Professional Services segment primarily consists of consultation services, including business registration and qualification-related services, and matchmaking services. The company was founded by Zhang Shugang on April 7, 2015 and is headquartered in Beijing, China.